Advertisement

Colon Cancer Medications

Here's a list of the approved drugs to treat colon cancer, also known as colorectal cancer. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Keytruda
GENERIC NAME pembrolizumab
DRUG INDICATION

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

DRUG Opdivo
GENERIC NAME nivolumab
DRUG INDICATION

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, metastatic small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, recurrent or metastatic esophageal cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

DRUG Yervoy
GENERIC NAME ipilimumab
DRUG INDICATION

Yervoy is a checkpoint inhibitor approved for advanced or metastatic melanoma, and in combination with Opdivo for kidney cancer (renal cell carcinoma), colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations (MSI-high/dMMR), advanced liver cancer and metastatic or recurrent non-small-cell lung cancer.

DRUG Avastin
GENERIC NAME bevacizumab
DRUG INDICATION

Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.

DRUG Braftovi
GENERIC NAME encorafenib
DRUG INDICATION

Braftovi is a kinase inhibitor approved as a component of targeted therapy for metastatic melanoma and metastatic colorectal cancer.

DRUG Cyramza
GENERIC NAME ramucirumab
DRUG INDICATION

Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.

DRUG Erbitux
GENERIC NAME cetuximab
DRUG INDICATION

Erbitux is an EGFR inhibitor approved for treatment of advanced or metastatic head and neck cancer and EGFR-positive metastatic colorectal cancer without KRAS mutations.

DRUG Rozlytrek
GENERIC NAME entrectinib
DRUG INDICATION

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Stivarga
GENERIC NAME regorafenib
DRUG INDICATION

Stivarga is a multikinase inhibitor approved for metastatic colorectal cancer, advanced or metastatic gastrointestinal stromal tumor (GIST) and liver cancer previously treated with Nexavar (sorafenib).

DRUG Vectibix
GENERIC NAME panitumumab
DRUG INDICATION

Vectibix is an EGFR inhibitor approved for treatment of metastatic colorectal cancer without RAS mutations.

DRUG Zaltrap
GENERIC NAME ziv-aflibercept
DRUG INDICATION

Zaltrap is a VEGF inhibitor approved for treatment of metastatic colorectal cancer that progresses after chemotherapy.


Advertisement